 |
|
 |
|
Talecris Biotherapeutics Recognized for Outstanding Achievement in Web Development
RESEARCH TRIANGLE PARK, N.C. (November 12, 2007) – Talecris Biotherapeutics, Inc. (www.talecris.com) received international recognition from the Web Marketing Association for excellence in Web site development of its product Web site, Prolastin.com (www.prolastin.com). Specifically, Prolastin.com received the award for Best Biotechnology Web site as part of the 2007 annual WebAward competition, a competition considered to be the premiere Web site award program available today. Prolastin® (Alpha1-Proteinase Inhibitor [Human]) is a plasma-derived therapy prescribed for adults diagnosed with alpha1-antitrypsin (AAT) deficiency, a leading genetic cause of chronic obstructive pulmonary disease (COPD). Talecris re-designed Prolastin.com in 2007 to improve the site’s usability and provide in-depth information for Alpha-1 patients and their caregivers.
“While physicians and patients have relied on Prolastin as a critical part of the total treatment regimen for 20 years, Talecris continually invests in new resources and programs, such as Prolastin.com, to provide further benefit to the Alpha-1 community,” said Nick Abruzzo, Associate Director, Global eMarketing, Talecris Biotherapeutics. “This recognition of Prolastin.com as the Best Biotechnology Web site of 2007 reinforces the simple functionality and comprehensive content we aimed for with the site’s re-design.”
There were more than 2,400 entries from 40 different countries submitted to the 2007 WebAward competition. Each entry was evaluated based on excellence in design, innovation, content, interactivity, ease of use, and use of technology.
Contact:
Lacy McMahon, Talecris Biotherapeutics
Tel.: 919.316.6316, Fax: 919.316.6673
E-mail: lacy.mcmahon@talecris.com
About Prolastin
Prolastin® is indicated for chronic augmentation therapy of individuals having congenital deficiency of alpha-1 proteinase inhibitor with clinically demonstrable panacinar emphysema. Individuals with selective IgA deficiencies who have known antibody against IgA should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
Important Safety Information
In clinical studies with Prolastin®, reactions (none severe) were observed in 1.16% of infusions, the most common events being fever, lightheadedness and dizziness. As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. For additional information on Prolastin®, please see full prescribing information at www.prolastin.com.
About Alpha1-Antitrypsin Deficiency
Alpha1-antitrypsin Deficiency, also known as AAT Deficiency or alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein AAT. It is most common in the Caucasian population of northern Europe and North America. AAT Deficiency is also the most common cause of genetic liver disease in children, and genetic emphysema (shortness of breath) in adults. Individuals suffering from AAT Deficiency often develop severe obstructive pulmonary disease (COPD) causing disability and premature death. AAT Deficiency affects some 150,000 people in North America and Europe.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.
To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|
|
|
|
|